Abstract. Insulin-deficient, streptozotocin-diabetic rats show severe metabolic disturbances and stop growing. Besides insulin, these animals also lack growth hormone and insulin-like growth factor-I. We examined whether or not growth parameters correlate with IGF
0.55). We found a highly significant linear correlation between IGF-I serum levels and the two investigated growth parameters, tibial epiphyseal width and longitudinal tibial bone growth. The finding that these indices of growth are strongly correlated with IGF-I serum levels in young rats with diabetes of different severity, suggests that IGF-I is a major determinant of growth. This is in keeping with our earlier demonstration that exogenously infused IGF-I promotes growth in diabetic rats.
Serum IGF-I levels are mainly controlled by growth hormone, insulin, nutrition, and age (1, 2, 3) . Reduced serum IGF-I levels are found in hypophysectomized and in diabetic rats. Both con¬ ditions are accompanied by growth arrest. Beside growth hormone, hypophysectomized rats also lack the other pituitary hormones. Streptozotocindiabetic rats are insulin-deficient and have low le¬ vels of GH and IGF-I (4, 5) .
In 1982, Schoenle et al. (6) demonstrated that subcutaneous infusion of human IGF-I during 6 days stimulated growth in hypophysectomized rats and thus provided evidence in favour of the somatomedin hypothesis (7) . Subsequently, it was shown that infusion of recombinant human IGF-I during 18 days had a sustained growth-promoting effect in hypophysectomized rats (8) .
Insulin treatment of streptozotocin-diabetic rats normalizes the metabolic condition, restores GH and IGF-I levels, and allows resumption of growth (9, 10) . Subcutaneously infused IGF-I imitates in¬ sulin with respect to growth promotion, but does not normalize blood glucose (9 (14) . Tetracycline (3.8 mg/kg Terravenös Pfizer, Zürich, Switzer¬ land) was injected ip. After 10 days, the rats were sacri¬ ficed, the undecalcified tibiae embedded in metacrylate, cut and abraded to 100 urn. Fianlly, the fluorescent tetra¬ cycline band in the bone was photographed at 400-fold magnification. The distance between the border of the epiphysis and the tetracycline band was measured. In some rats, fluorescent bands were missing as also re¬ ported by Hansson et al. (14) . Plotting tibial epiphyseal width as a function of the IGF-I serum level revealed a highly significant linear correlation (Fig. 2, r (4, 5) . In¬ sulin treatment normalizes the metabolic disturb¬ ance, restores the GH secretory pattern and the IGF-I serum levels, and allows resumption of growth (9, 10) . In contrast, GH-treatment of diabetic rats fails to raise low IGF-I serum levels and has no growth-promoting effects on bone and cartilage (9) . Since IGF-I is mainly produced by the liver under the influence of GH (15, 16) , this responsiveness to GH must be impaired in diabetes. In fact, IGF-I secretion by the diabetic rat liver was found to be markedly reduced (17) (18) (19) . Apart from the liver, other tissues, particularly bone and car¬ tilage, synthesize and secrete IGF-I under the in¬ fluence of GH (20) (21) (22) (23) (24) . This mechanism involved in autocrine/paracrine stimulation of growth may also be impaired in the streptozotocin-diabetic rats and restored by insulin-treatment. It is likely that insulin acts indirectly via an increase in IGF-I syn¬ thesis on growth of diabetic rats, by means of re¬ storing GH secretion and the responsiveness of the liver to GH. Evidence for this was provided by the finding that subcutaneous infusion of IGF-I stimu¬ lated growth of insulin-deficient diabetic rats des¬ pite persisting hyperglycemia (9) .
In the study by Scheiwiller et adaequate measure for the severity of diabetes. A better measure would be the integrated insulin re¬ lease over 24 hours. The latter probably deter¬ mines the serum IGF-I levels which show a highly significant linear correlation with the studied growth parameters. These results are in agreement with the finding that exogenous IGF-I stimulates the growth of diabetic rats and support the notion that IGF-I is an important mediator of the growth promoting effects of growth hormone (hypophys¬ ectomized rat, 6, 8) and insulin (diabetic rat, 9).
